

Impacts on growth and constipation after transitioning to Neocate® Syneo®



Jenelle Fernandez, MD
Pediatric
Gastroenterologist,
Assistant Professor
Mobile, Alabama

Patient History:

A 3-month-old female was born full term via vaginal delivery without complications. She was initially on Enfamil®; however, her primary care physician (PCP) transitioned her to Alimentum® due to a suspected cow milk allergy (CMA) with the family reporting constipation and eczema. While on Alimentum she continued to struggle with constipation and began to have episodes of emesis after each feed. The PCP started the patient on milk of magnesia and transitioned the patient to EleCare®. The family stated that she became very fussy and began refusing bottles. The PCP subsequently transitioned the patient to Neocate® Syneo® Infant at the standard concentration, started famotidine 0.5 mg/kg daily, transitioned to MiraLAX® and placed a Pediatric Gastroenterology (GI) referral.



Nutritional Management:

During the initial Pediatric GI visit, her weight was 4.26 kg with a weight z-score of -2.78 and weight for length z-score of -2.96 which qualified patient as moderately malnourished. Based on previous PCP records, the patient's birth weight was noted at 25th percentile with initial visit weight at Pediatric GI office noted at 0.2 percentile. With a food recall, the family reported allowing the patient to sleep approximately 13 hours overnight. The GI discussed concentrating Neocate Syneo to 27 kcal/oz and assuring she gets fed a minimum of 8 feeds per day which should include overnight feeds. Famotidine was adjusted to 0.5 mg/kg twice daily.


At the follow up visit 2 weeks later she showed an average weight gain of 77 g/d with minimal spit up. Her weight was noted at 4.8 kg with weight z-score of -2.02 and weight-for-length z-score of -2.85. The family expressed that they would like to allow her to sleep overnight so feeds were decreased from 8 times per day to 6 times per day.

At her follow up appointment two weeks later, the patient was gaining an average of 41 g/d. With a weight of 5.38 kg, weight z-score of -1.44 and weight-for-length z score of -1.51 and she was now diagnosed with mild malnutrition. The family was no longer using MiraLAX for constipation as she was stooling daily on Neocate Syneo. The family voiced that her eczema had greatly improved over the last few weeks. The patient's reflux was also now described as minimal. She continued with Neocate Syneo but due to improved weight gain the caloric density was decreased to 24 kcal/oz.

Conclusion:

This case documents success using Neocate Syneo Infant to manage reflux and eczema in a patient with suspected cow milk allergy with a complex medical history. Neocate Syneo Infant with prebiotics and probiotics also may have helped improve constipation in this patient. The patient's growth and reflux improved with Neocate Syneo Infant and proper pharmacologic interventions.

CDC's WHO Weight-for-age, 0-2 years, Girls



Brought to you by Nutricia North America.

The opinions expressed are those of the author of this case study and not necessarily reflective of the views of Nutricia North America. Formula choices were made independently prior to the author's development of this patient case report. Neocate® is a family of hypoallergenic, amino acid-based medical foods and is intended for use under medical supervision.

Alimentum and EleCare are registered trademarks of Abbott Laboratories and are not affiliated with Nutricia North America.

MiraLAX is a registered trademark of Bayer and not affiliated with Nutricia North America.

© 2025 Nutricia North America

Request Neocate
samples online:

